{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:05:53Z","timestamp":1770483953775,"version":"3.49.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,8,1]],"date-time":"2010-08-01T00:00:00Z","timestamp":1280620800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2010,8]]},"DOI":"10.1016\/j.clinthera.2010.08.008","type":"journal-article","created":{"date-parts":[[2010,10,26]],"date-time":"2010-10-26T08:45:34Z","timestamp":1288082734000},"page":"1578-1596","source":"Crossref","is-referenced-by-count":19,"title":["Dexlansoprazole: A proton pump inhibitor with a dual delayed-release system"],"prefix":"10.1016","volume":"32","author":[{"given":"Christopher R.","family":"Emerson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nino","family":"Marzella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2010.08.008_bib1","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/j.1572-0241.2005.41217.x","article-title":"Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease","volume":"100","author":"DeVault","year":"2005","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.clinthera.2010.08.008_bib2","first-page":"CD003245","article-title":"Medical treatments for the maintenance therapy of reflux oesophagitis and endoscopic negative reflux disease","author":"Donnellan","year":"2004","journal-title":"Cochrane Database Syst Rev."},{"key":"10.1016\/j.clinthera.2010.08.008_bib3","first-page":"710","article-title":"Epidemiology of gastro-oesophageal reflux disease: A systematic review","volume":"54","author":"Dent","year":"2005","journal-title":"Cut"},{"key":"10.1016\/j.clinthera.2010.08.008_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2036.2005.02531.x","article-title":"Systematic review: Proton-pump inhibitor failure in gastro-oesophageal reflux disease\u2014where next?","volume":"22","author":"Fass","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2010.08.008_bib5","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMcp012118","article-title":"Clinical practice. Barrett's esophagus","volume":"346","author":"Spechler","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2010.08.008_bib6","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1111\/j.1572-0241.2008.01835.x","article-title":"Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus","volume":"103","author":"Wang","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2010.08.008_bib7","first-page":"128","article-title":"Barrett's esophagus and risk of esophageal adenocarcinoma","volume":"14","author":"Cossentino","year":"2003","journal-title":"Semin Gastrointest Dis"},{"key":"10.1016\/j.clinthera.2010.08.008_bib8","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1056\/NEJM199903183401101","article-title":"Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma","volume":"340","author":"Lagergren","year":"1999","journal-title":"N Engl J Med."},{"key":"10.1016\/j.clinthera.2010.08.008_bib9","author":"Spechler"},{"key":"10.1016\/j.clinthera.2010.08.008_bib10","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1542-3565(04)00288-5","article-title":"Effectiveness of proton pump inhibitors in nonerosive reflux disease","volume":"2","author":"Dean","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2010.08.008_bib11","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2036.2006.02944.x","article-title":"Review article: Acidrelated disease\u2014what are the unmet clinical needs?","volume":"23","author":"Katz","year":"2006","journal-title":"Aliment Pharmacol Ther."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.08.008_bib12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/j.1365-2036.2005.02715.x","article-title":"Review article: The unmet needs in delayed-release proton-pump inhibitor therapy in 2005","volume":"22","author":"Hunt","year":"2005","journal-title":"Ailment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2010.08.008_bib13","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1572-0241.2002.05532.x","article-title":"Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis","volume":"97","author":"Castell","year":"2002","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2010.08.008_bib14","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1572-0241.2001.03600.x","article-title":"Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: A randomized controlled trial","volume":"96","author":"Richter","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2010.08.008_bib15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1365-2036.2005.02339.x","article-title":"Efficacy of esomeprazole 40 mg vs. lansoprazole 30 mg for healing moderate to severe erosive oesophagitis","volume":"21","author":"Fennerty","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2010.08.008_bib16","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1365-2036.2005.02368.x","article-title":"A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: The EXPO study","volume":"21","author":"Labenz","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2010.08.008_bib17","series-title":"Aciphex (rabeprazole) [package insert]","year":"2009"},{"key":"10.1016\/j.clinthera.2010.08.008_bib18","series-title":"Nexium (esomeprazole) [package insert]","year":"2009"},{"key":"10.1016\/j.clinthera.2010.08.008_bib19","series-title":"Prilosec (omeprazole) [package insert]","year":"2008"},{"key":"10.1016\/j.clinthera.2010.08.008_bib20","series-title":"Protonix (pantoprazole) [package insert]","year":"2008"},{"key":"10.1016\/j.clinthera.2010.08.008_bib21","series-title":"Prevacid (lansoprazole) [package insert]","year":"2009"},{"key":"10.1016\/j.clinthera.2010.08.008_bib22","series-title":"Kapidex (dexlansoprazole) [package insert]","year":"2009"},{"key":"10.1016\/j.clinthera.2010.08.008_bib23","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1111\/j.2042-7158.1998.tb03340.x","article-title":"Pharmacokinetic differences between lansoprazole enantiomers in rats","volume":"50","author":"Arimori","year":"1998","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.clinthera.2010.08.008_bib24","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1248\/bpb.24.274","article-title":"Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs","volume":"24","author":"Masa","year":"2001","journal-title":"Biol Pharm Bull."},{"key":"10.1016\/j.clinthera.2010.08.008_bib25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1185\/03007990802693883","article-title":"Pharmacokinetics and pharmacodynamics of a known active PPI with a novel dual delayed release technology, dexlansoprazole MR: A combined analysis of randomized controlled clinical trials","volume":"25","author":"Vakily","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"Suppl 2S","key":"10.1016\/j.clinthera.2010.08.008_bib26","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.14309\/00000434-200709002-00015","article-title":"TAK-390MR vs lansoprazole (LAN) for maintenance of drug concentration above a threshold which corresponds to higher %-time pH >4","volume":"102","author":"Wu","year":"2007","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2010.08.008_bib27","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1111\/j.1365-2036.2009.03979.x","article-title":"Clinical trial: The effect and timing of food on the pharmacokinetics and pharmacodynamics of dexlansoprazole MR, a novel Dual Delayed Release formulation of a proton pump inhibitor\u2014evidence for dosing flexibility","volume":"29","author":"Lee","year":"2009","journal-title":"Aliment Pharmacol Ther."},{"issue":"Suppl 1S","key":"10.1016\/j.clinthera.2010.08.008_bib28","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.14309\/00000434-200809001-00012","article-title":"TAK-390MR, a novel dual delayed release formulation of a PPI, is bioequivalent when administered as granules sprinkled over applesauce or as an intact capsule","volume":"103","author":"Czerniak","year":"2008","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.08.008_bib29","first-page":"194","article-title":"Metabolism and excretion of (14C) TAK-390 in healthy male subjects","volume":"40","author":"Grabowski","year":"2008","journal-title":"DrugMetab Rev"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.08.008_bib30","first-page":"S95","article-title":"Effect of hepatic impairment on the pharmacokinetics of TAK-390MR (modified release)","volume":"83","author":"Lee","year":"2008","journal-title":"Clin Pharmacol Ther."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.08.008_bib31","first-page":"S96","article-title":"Effect of age and gender on the pharmacokinetics of a single oral dose of TAK-390MR (modified release)","volume":"83","author":"Vakily","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.08.008_bib32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2165\/0044011-200929010-00004","article-title":"Drug interaction studies with dexlansoprazole modified release (TAK-390MR), a proton pump inhibitor with a dual delayed-release formulation: Results of four randomized, double-blind, crossover, placebo-controlled, single-centre studies","volume":"29","author":"Vakily","year":"2009","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.clinthera.2010.08.008_bib33","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/S0140-6736(09)61525-7","article-title":"Pharmacodynamic effect and clinical efficacy of Clopidogrel and prasugrel with or without a proton-pump inhibitor: An analysis of two randomised trials","volume":"374","author":"O\u2019Donoghue","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2010.08.008_bib34","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1503\/cmaj.082001","article-title":"A population-based study of the drug interaction between proton pump inhibitors and Clopidogrel","volume":"180","author":"Juurlink","year":"2009","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2010.08.008_bib35","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1001\/jama.2009.261","article-title":"Risk of adverse outcomes associated with concomitant use of Clopidogrel and proton pump inhibitors following acute coronary syndrome","volume":"301","author":"Ho","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2010.08.008_bib36","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.jacc.2007.06.064","article-title":"Influence of omeprazole on the antiplatelet action of Clopidogrel associated with aspirin: The randomized, double-blind OCLA (Omeprazole CLopidogrel Aspirin) Study","volume":"51","author":"Guard","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.clinthera.2010.08.008_bib37","series-title":"Plavix (Clopidogrel) [package insert]","year":"2009"},{"key":"10.1016\/j.clinthera.2010.08.008_bib38","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1177\/0091270008330155","article-title":"Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects","volume":"49","author":"Zhang","year":"2009","journal-title":"J Clin Pharmacol."},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.08.008_bib39","first-page":"S26","article-title":"Effects of TAK-390MR on plasma gastrin levels in healthy adults","volume":"81","author":"Zhang","year":"2007","journal-title":"Clin Pharmacol Ther."},{"key":"10.1016\/j.clinthera.2010.08.008_bib40","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1177\/0091270009339188","article-title":"Lack of electrocardiographic effect of dexlansoprazole MR, a novel modifiedrelease formulation of the proton pump inhibitor dexlansoprazole, in healthy participants","volume":"49","author":"Vakily","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2010.08.008_bib41","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1111\/j.1365-2036.2009.03933.x","article-title":"Clinical trials: Healing of erosive oesophagitis with dexlansoprazole MR, a proton pump inhibitor with a novel dual delayed-release formulation\u2014results from two randomized controlled studies","volume":"29","author":"Sharma","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2010.08.008_bib42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1111\/j.1365-2036.2009.03954.x","article-title":"Clinical trial: Dexlansoprazole MR, a proton pump inhibitor with dual delayed-release technology, effectively controls symptoms and prevents relapse in patients with healed erosive oesophagitis","volume":"29","author":"Metz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2010.08.008_bib43","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.14309\/00000434-200809001-00057","article-title":"TAK-390MR maintains relief of gastroesophageal reflux disease (GERD) symptoms and improvements in quality of life in GERD patients with healed erosive esophagitis","volume":"103","author":"Mody","year":"2008","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2010.08.008_bib44","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1111\/j.1365-2036.2009.04119.x","article-title":"Clinical trial: Efficacy and safety of dexlansoprazole MR 60 and 90 mg in healed erosive oesophagitis\u2014maintenance of healing and symptom relief","volume":"30","author":"Howden","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2010.08.008_bib45","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1111\/j.1365-2036.2009.04013.x","article-title":"Clinical trial: The effects of the proton pump inhibitor dexlansoprazole MR on daytime and nighttime heartburn in patients with nonerosive reflux disease","volume":"29","author":"Fass","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.08.008_bib46","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.14309\/00000434-200910003-00029","article-title":"Dexlansoprazole MR for treatment for nocturnal heartburn in patients with symptomatic nonerosive GERD","volume":"104","author":"Fass","year":"2009","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.08.008_bib47","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.14309\/00000434-200910003-00030","article-title":"Effects of dexlansoprazole MR on sleep quality and health-related quality of life (HRQOL) in patients with symptomatic nonerosive GERD","volume":"104","author":"Orr","year":"2009","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.08.008_bib48","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.14309\/00000434-200910003-00031","article-title":"Effect of dexlansoprazole MR on improving work productivity and daily activities in patients with symptomatic nonerosive GERD","volume":"104","author":"Johnson","year":"2009","journal-title":"Am J Gastroenterol."},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2010.08.008_bib49","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.14309\/00000434-200910003-00013","article-title":"Gastric biopsy results from patients treated with dexlansoprazole MR, a proton pump inhibitor with a dual delayed release formulation","volume":"104","author":"Bronner","year":"2009","journal-title":"Am J Gastroenterol."},{"key":"10.1016\/j.clinthera.2010.08.008_bib51","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1111\/j.1365-2036.2009.03984.x","article-title":"Review article: Dual delayed release formulation of dexlansoprazole MR, a novel approach to overcome the limitations of conventional single release proton pump inhibitor therapy","volume":"29","author":"Metz","year":"2009","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2010.08.008_bib52","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1111\/j.1572-0241.2003.08783.x","article-title":"Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: A five-way crossover study","volume":"98","author":"Miner","year":"2003","journal-title":"Am J Gastroenterol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810002936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291810002936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T09:06:57Z","timestamp":1592039217000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291810002936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,8]]},"references-count":51,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,8]]}},"alternative-id":["S0149291810002936"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2010.08.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2010,8]]}}}